Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects - Kubitza, D; Becka, M; Zuehlsdorf, M (J Clin Pharmacol, 2007)